Spironolactone for Heart Failure with Preserved Ejection Fraction

20142,662 citationsJournal Articlebronze Open Access

Authors

Bertram Pitt · University of Michigan–Ann Arbor

Marc A. Pfeffer · Brigham and Women's Hospital

Susan F. Assmann · New England Research Institutes

Robin Boineau · National Heart Lung and Blood Institute

Inder S. Anand · University of Minnesota Medical Center

Brian Claggett · Brigham and Women's Hospital

Nadine Clausell

Abstract

In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.).

Topics & Keywords

Hormonal Regulation and Hypertension Heart Failure Treatment and Management Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 15, pp. 1383-1392

DOI: 10.1056/nejmoa1313731

Field-Weighted Citation Impact: 126.15